RecruitingPeripartum Cardiomyopathy, Postpartum
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Eligible age
18+ yrs
Accepts
Women
Locations
31 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Sponsor: Dennis M. McNamara, MD, MS
You may qualify if…
- ✓ 1. Presentation with a new diagnosis of peripartum cardiomyopathy
- ✓ 2. Post-delivery and within the first 5 months post-partum.
- ✓ 3. Clinical assessment of an LVEF \< or =0.40 within 4 weeks of consent for randomized control trial
- ✓ 4. Clinical assessment of an LVEF \< or =0.40 within 8 weeks of consent for breastfeeding cohort
- ✓ 5. Age \> or = 18.
You may not qualify if…
- ✕ 1. Previous diagnosis of cardiomyopathy, valvular disease or congenital heart disease (with the exception of women with a history of peripartum cardiomyopathy with complete recovery and a documented LVEF \> 0.55 prior to or in early pregnancy)
- ✕ 2. Refractory hypertension (Systolic \>160 or Diastolic \> 95) either at the time of enrollment or at the time of the qualifying LVEF.
- ✕ 3. Postpartum women currently breastfeeding and planning to continue.
- ✕ 4. Evidence of coronary artery disease (\>50% stenosis of major epicardial vessel or positive non-invasive stress test)
- ✕ 5. Previous cardiac transplant
- ✕ 6. Current durable LVAD support
- ✕ 7. Currently requiring support with extracorporeal membrane oxygenation (ECMO)
- ✕ 8. Current history of alcohol or drug abuse
Where it's recruiting
Source: ClinicalTrials.gov · NCT05180773 · last updated 2026-08-10